A Case of Herpetic Simplex Keratitis after Application of 0.015% Tafluprost Eye Drops

Ho Gyun Park; Sangkyung Choi

doi:10.3341/jkos.2013.54.12.1950

Journal List > J Korean Ophthalmol Soc > v.54(12) > 1009576

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park and Choi: A Case of Herpetic Simplex Keratitis after Application of 0.015% Tafluprost Eye Drops

Original Article

J Korean Ophthalmol Soc 2013;54(12):1950-1953.

Published online: 7 September 2013

DOI: https://doi.org/10.3341/jkos.2013.54.12.1950

A Case of Herpetic Simplex Keratitis after Application of 0.015% Tafluprost Eye Drops

Ho Gyun Park, MD, Sangkyung Choi, MD

Department of Ophthalmology, Veterans Health Service Medical Center, Seoul, Korea

Address reprint requests to Sangkyung Choi, MD Department of Ophthalmology, Veterans Health Service Medical Center, #53 Jinhwangdo-ro 61-gil, Gangdong-gu, Seoul 134-791, Korea, Tel: 82-2-2225-1382, Fax: 82-2-2225-1485, E-mail: drskchoi@hanmail.net

Received 16 May 201325 June 2013 Accepted 4 November 2013

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To report a single case of herpes simplex keratitis after application of 0.015% tafluprost eye drops.

Case summary

A 68-year-old male presented with left eye discomfort, epiphora, decreased visual acuity and hyperemia. The patient was diagnosed with glaucoma 6 weeks prior and started on 0.015% tafluprost eye drops in left eye and 0.15% brimonidine in both eyes. On slit lamp examination dendritic epithelial defect was observed and the patient was diagnosed with herpes simplex keratitis. The 0.015% tafluprost treatment was discontinued and 0.15% brimonidine was applied in both eyes twice a day. The herpetic keratitis in his left eye resolved completely in 2 weeks with acyclovir ointment and oral antiviral agent. No further recurrence was observed in the following 3 months.

Keywords: Brimonidine, Herpetic simplex keratitis, Tafluprost

References

1. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes sim-plex keratitis. Am J Ophthalmol. 1999; 127:602–4.

2. Ekatomatis P. Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma. Br J Ophthalmol. 2001; 85:1007–12.

3. Dios CE, Maquet DJ. Latanoprost-associated recurrent herpes sim-plex keratitis. Arch Soc Esp Oftalmol. 2000; 75:775–8.

4. Asensio Sánchez VM. Recurrent corneal keratitis associated with the use of latanoprost. Arch Soc Esp Oftalmol. 2001; 76:277.

5. Villegas VM, Diaz L, Izquierdo NJ. Herpetic keratitis in a patient who used two different prostaglandin analogue ophthalmic sol-utions: a case report. PR Health Sci J. 2008; 27:348–9.

6. Kroll DM, Schuman JS. Reactivation of herpes simplex virus kera-titis after initiating bimatoprost treatment for glaucoma. Am J Ophthalmol. 2002; 133:401–3.

7. Kothari MT, Mehta BK, Asher NS, Kothari KJ. Recurrence of bi-lateral herpes simplex virus keratitis following bimatoprost use. Indian J Ophthalmol. 2006; 54:47–8.

8. Kaye S, Choudhary A. Herpes simplex keratitisㅍ. Prog Retin Eye Res. 2006; 25:355–80.

9. Byon IS, Lee JE, Lee JS. Treatment of herpes simplex ocular dis-ease with ganciclovir ophthalmic gel. J Korean Ophthalmol Soc. 2005; 46:164–70.

10. Lee GU, Lee JH. Corticosteroid therapy in herpes simplex virus keratitis. J Korean Ophthalmol Soc. 1986; 27:493–6.

11. Dhaliwal DK, Romanowski EG, Yates KA. . Experimental laser-assisted in situ keratomileusis induces the reactivation of latent herpes simplex virus. Am J Ophthalmol. 2001; 131:506–7.

12. Krachmer JH, Mannis M, Holland E. Cornea. 2nd ed.Philadelphia: Elsevier Mosby;v. 1:2005; 1045–6.

13. Strober BE, Potash S, Grossman ME. Eyelash hypertrichosis in a patient treated with topical latanoprost. Cutis. 2001; 67:109–10.

14. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol. 1997; 115:1206–8.

15. Hejkal TW, Camras CB. Prostaglandin analogs in the treatment of glaucoma. Semin Ophthalmol. 1999; 14:114–23.

16. Furuichi M, Chiba T, Abe K. . Cystoid macular edema asso-ciated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier. J Glaucoma. 2001; 10:233–6.

17. Kaufman HE, Varnell ED, Toshida H. . Effects of topical unoprostone and latanoprost on acute and recurrent herpetic keratitis in the rabbit. Am J Ophthalmol. 2001; 131:643–6.

18. Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol. 1999; 127:531–6.

19. Kim KE, Moon JI, Chung SK, Baek NH. 3 cases of latanoprost as-sociated herpes simplex keratitis. J Korean Ophthalmol Soc. 2002; 43:1081–5.

20. Harbour DA, Blyth WA, Hill TJ. Prostaglandins enhance spread of herpes simplex virus in cell cultures. J Gen Virol. 1978; 41:87–95.

21. O'Brien WJ, Taylor JL, Ankel H, Sitenga G. Assessment of antiviral activity, efficacy, and toxicity of prostaglandin A2 in a rabbit model of herpetic keratitis. Antimicrob Agents Chemother. 1996; 40:2327–31.

22. Hill JM, Shimomura Y, Kwon BS, Gangarosa LP. Iontophoresis of epinephrine isomers to rabbit eyes induced HSV-1 ocular shedding. Invest Ophthalmol Vis Sci. 1985; 26:1299–303.

23. Nakajima T, Matsugi T, Goto W. . New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull. 2003; 26:1691–5.

24. Yang HS, Park HG, Choi SK. Reactivation of herpetic keratitis in a patient after using two different prostaglandin analogues. J Korean Ophthalmol. 2011; 52:1119–22.

Figure 1.

A 68-year-old male with dendritic keratitis after using 0.015% tafluprost for 1 month.

Figure 2.

Resolving state of dendritic keratitis after discontinuing of 0.015% tafluprost eye drop for 2 weeks.

TOOLS

Similar articles